|
Market Closed -
Nasdaq Stockholm
15:30:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 3.600 SEK | +2.86% |
|
+7.46% | +144.90% |
Company Valuation: Sprint Bioscience AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 191.1 | 22.03 | 121.1 | 110.5 | 155.1 | 379.9 | - |
| Change | - | -88.47% | 449.78% | -8.82% | 40.43% | 144.9% | - |
| Enterprise Value (EV) | 120.4 | -7.459 | 71.2 | 85.4 | 155.1 | 379.9 | 379.9 |
| Change | - | -106.19% | 1,054.57% | 19.94% | 81.63% | 144.9% | 0% |
| P/E | -5.64x | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.44x | 265x | 2.4x | 1.68x | 0.93x | 4.38x | 3.92x |
| EV / Revenue | 0x | -0x | 0x | 0x | 0x | 4.38x | 3.92x |
| EV / EBITDA | -0x | 0x | -0x | -0x | 0x | 14.2x | 9.87x |
| EV / EBIT | -0x | 0x | -0x | -0x | 0x | 14.8x | 10.1x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.85 | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 35.11 | 0.083 | 50.48 | 65.64 | 167.2 | 86.8 | 96.8 |
| EBITDA 1 | -25.04 | -60.12 | -0.398 | -18.71 | 98.36 | 26.8 | 38.5 |
| EBIT 1 | -25.63 | -60.74 | -0.845 | -19.67 | 97.29 | 25.7 | 37.5 |
| Net income | -25.08 | - | - | - | - | - | - |
| Net Debt | -70.64 | -29.49 | -49.93 | -25.06 | - | - | - |
| Reference price 2 | 4.795 | 0.553 | 1.735 | 1.582 | 1.470 | 3.600 | 3.600 |
| Nbr of stocks (in thousands) | 39,844 | 39,844 | 69,820 | 69,820 | 105,516 | 105,516 | - |
| Announcement Date | 2/16/22 A | 2/15/23 A | 2/14/24 A | 2/12/25 A | 2/11/26 A | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 37.46M | |
| 16.97x | 6.42x | 12.3x | 1.76% | 64.38B | |
| 30.03x | 8.21x | 26.91x | 0.04% | 56.16B | |
| 37.32x | 6.62x | 19.78x | 0.87% | 54.16B | |
| 35.94x | 3.4x | 14.66x | -.--% | 45.33B | |
| 49.01x | 5.65x | 30.93x | -.--% | 42.25B | |
| -19.75x | 191.25x | -21.04x | -.--% | 40.78B | |
| 46.05x | 8.16x | 27.33x | -.--% | 33.8B | |
| 31.61x | 8.04x | 20.91x | 0.41% | 32.25B | |
| 27.18x | 5.72x | 14.84x | -.--% | 23.57B | |
| Average | 28.26x | 27.05x | 16.29x | 0.34% | 39.27B | |
| Weighted average by Cap. | 27.79x | 25.71x | 16.39x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRINT Stock
- Valuation Sprint Bioscience AB
Select your edition
All financial news and data tailored to specific country editions
